City
Epaper

Serum Institute dispatches over 90 per cent vaccines ordered by govt

By ANI | Updated: January 13, 2021 15:30 IST

Serum Institute of India (SII) has dispatched over 90 per cent of the COVID-19 vaccine, Covishield, oreder by the Government of India.

Open in App

Serum Institute of India (SII) has dispatched over 90 per cent of the COVID-19 vaccine, Covishield, oreder by the Government of India.

Official sources confirmed to that about 10.99 million doses have been already dispatched from SII facility in Pune and only around 90,000 doses are left to be dispatched.

Sources have also confirmed that the remaining volume of the vaccines will be dispatched either on Wednesday or Thursday from the SII facility.

The Government of India had placed an order for 11 million doses from the SII earlier at a price of Rs 200 per dose (only for first 11 million doses).

Dispatch of the vaccines started on Tuesday from the SII facility in Pune and was taken to almost 13 locations with nine different flights from Pune International Airport.

According to official sources involved in the transport of the vaccine, three trucks reached Mumbai Airport early on Wednesday morning. About 26 locations across the country will receive the vaccine from Mumbai airport through various flights today and six more locations will be delivered vaccines from Pune International airport.

The location that will receive vaccine shipments today include Raipur, Rajkot, Kurukshetra, Ranchi, Cochin, Kozhikode, Thiruvananthapuram, Varanasi, Jaipur, Port Blair, Shimla, Srinagar, Leh, Imphal, Agartala and several others.

The Maharashtra government provided road transport for their part of delivery and their cold chain storage facility is based at a few kilometers from SII's facility in Pune. Health department officials have confirmed that they have received 9.63 lakh doses and the same will be distributed to various districts and municipal corporations across the state.

Covishield and Covaxin, the two COVID-19 vaccines, which have received Emergency Use Authorisation (EAU), have been tested on thousands of people and side-effects are negligible, Dr VK Paul, Member (Health), NITI Aayog, said on Tuesday and noted that the two "are safest of the vaccines".

"Both the vaccines (Covishield and Covaxin) have been authorised for emergency use and there should be no doubt about their safety. They have been tested on thousands of people and side-effects are negligible. There is no risk of any significance," Dr Paul said at a press conference here.

The first phase of the COVID-19 vaccination drive is scheduled to start from January 16 onwards.

Earlier, Health Secretary Rajesh Bhushan had said the central government is having close collaboration with states and Union Territories for vaccine roll-out. "All preparations are on track for vaccine roll-out from January 16," he had said.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Rajesh bhushanpunemumbaiSIISerum Institute Of IndiaMumbai puneSerum institute of india pvt. ltdSerum india
Open in App

Related Stories

PunePune Accident: Minor Girl Dies After Being Run Over by Car While Parking in Shed

PunePune News: School Bus Loses Control, Hits Electric Pole; Several Students Injured

PunePune Horror: Man Arrested for Alleged Sexual Assault on 7-Year-Old Girl in Moshi

MumbaiMumbai: Customer Bites Vendor’s Fingers During Bill Dispute Over Samosa in Malad

MumbaiMumbai Local Train Update: Special Night Block on Western and Central Lines for Prabhadevi Bridge Demolition

National Realted Stories

National"Light diesel oil, bitumen shortage will hit construction costs": Himachal PWD Minister

National"LDF is going to win": CPI(M) leader Thomas Isaac

NationalRailways approves Rs 398 cr Optical Fibre Project to boost communication network

NationalIndian Railways registers strong FY26 growth with record freight, passenger gains

NationalJamiat’s remarks against us are ‘deeply unfortunate’: AIMIM